Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size By Type (Gattex, Revestive), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Glucagon-like Peptide-2 (GLP-2) Agonist Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 2.9 billion by 2031, growing at a CAGR of 13.0% during the forecast period of 2023 to 2031. The market is being driven by the increasing prevalence of gastrointestinal (GI) disorders, particularly Short Bowel Syndrome (SBS), the rising geriatric population, and advancements in peptide-based therapeutics. GLP-2 agonists are gaining attention for their ability to improve intestinal absorption and reduce dependence on parenteral nutrition, positioning them as a breakthrough in rare disease treatment protocols.

Drivers:

Rising Prevalence of Gastrointestinal Disorders:

An increasing number of cases related to intestinal failure, Crohn’s disease, and Short Bowel Syndrome has driven the demand for GLP-2 agonist therapies. These agonists promote intestinal growth and nutrient absorption, offering patients a better quality of life.

Advancements in Peptide Therapeutics:

Continuous innovation in peptide engineering and delivery systems has led to improved bioavailability and reduced dosing frequency of GLP-2 agonists, making them more effective and patient-friendly.

Favorable Regulatory Support:

Global health agencies, including the FDA and EMA, have granted orphan drug status and fast-track designations to several GLP-2 therapies, accelerating their clinical development and commercialization.

Restraints:

High Cost of Therapy:

GLP-2 agonists are considered specialty drugs, often associated with high treatment costs that may not be covered entirely by insurance. This acts as a barrier, especially in developing regions.

Limited Awareness and Diagnosis:

Despite promising clinical outcomes, the adoption of GLP-2 therapies is hindered by low awareness levels among healthcare providers and patients, particularly in rural and underdeveloped healthcare systems.

Opportunity:

Emerging Markets and Untapped Patient Pools:

Regions such as Asia-Pacific and Latin America offer significant growth opportunities due to increasing healthcare expenditure and improved diagnostic capabilities. Pharmaceutical companies are also focusing on expanding access in these regions.

Pipeline Development and Strategic Collaborations:

With several GLP-2 agonists in various stages of clinical trials, strategic partnerships among biotech firms and larger pharmaceutical companies are likely to accelerate innovation and broaden the therapeutic landscape.

Market by System Type Insights:

Based on system type, the Injectable GLP-2 Agonists segment dominated the market in 2023. This dominance is attributed to the clinical efficacy and FDA approvals of injectable formulations like teduglutide. Although oral peptide delivery remains a challenge, ongoing research is paving the way for non-invasive alternatives, expected to transform the treatment landscape in the coming years.

Market by End-use Insights:

The Hospital and Specialty Clinics segment was the largest end-use contributor in 2023. These healthcare settings are pivotal in managing complex GI disorders, including Short Bowel Syndrome, where GLP-2 agonist administration requires regular monitoring and nutritional support. The Homecare segment is also anticipated to grow significantly as self-administration devices become more advanced and user-friendly.

Market by Regional Insights:

North America led the GLP-2 agonist market in 2023, fueled by advanced healthcare infrastructure, higher awareness, and the presence of key pharmaceutical players. The Asia-Pacific region is projected to witness the highest CAGR during the forecast period due to the rising prevalence of digestive diseases, increasing investments in biotech research, and improving access to rare disease therapies.

Competitive Scenario:

Key players in the Global GLP-2 Agonist Market include:

Takeda Pharmaceutical Company Limited

Zealand Pharma A/S

Hanmi Pharmaceutical Co., Ltd.

Ironwood Pharmaceuticals, Inc.

Pfizer Inc.

Amgen Inc.

These companies are investing heavily in R&D, clinical trials, and geographic expansion. For instance:

Takeda’s Revestive (teduglutide) continues to expand its indications globally.

Zealand Pharma is advancing its next-gen GLP-2 analogs with improved dosing profiles.

In 2024, Ironwood Pharmaceuticals entered a licensing agreement to co-develop oral GLP-2 formulations.

Scope of Work – Global Glucagon-like Peptide-2 (GLP-2) Agonist Market

Report Metric Details

Market Size (2023) USD 1.1 Billion

Projected Market Size (2031) USD 2.9 Billion

CAGR (2023–2031) 13.0%

Key Segments By System Type (Injectable, Oral Pipeline), By End-use (Hospitals, Specialty Clinics, Homecare), By Region

Growth Drivers Increasing GI disease prevalence, peptide drug advancements, regulatory support

Opportunities Pipeline innovations, expansion into emerging markets

Key Market Developments:

2023: Zealand Pharma announced positive Phase II trial results for its next-generation GLP-2 analog, showing improved efficacy over current therapies.

2024: Takeda expanded Revestive's market access across key Latin American countries through strategic pricing and reimbursement agreements.

2025: Hanmi Pharmaceutical revealed an innovative depot formulation of GLP-2 agonist aimed at reducing injection frequency from daily to monthly.

FAQs:

1) What is the current market size of the Global Glucagon-like Peptide-2 (GLP-2) Agonist Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Glucagon-like Peptide-2 (GLP-2) Agonist Market?

The key growth driver is the rising prevalence of gastrointestinal disorders, particularly Short Bowel Syndrome.

3) Which is the largest region during the forecast period in the Global GLP-2 Agonist Market?

North America is the largest region, supported by advanced healthcare infrastructure and strong regulatory pathways.

4) Which segment accounted for the largest market share in the Global GLP-2 Agonist Market?

The Injectable GLP-2 Agonists segment dominated the market in 2023.

5) Who are the key market players in the Global Glucagon-like Peptide-2 (GLP-2) Agonist Market?

Key players include Takeda, Zealand Pharma, Hanmi Pharmaceutical, Ironwood Pharmaceuticals, Pfizer, and Amgen.